SM19712 free acid

SM19712 free acid 是一种具有口服活性的选择性内皮素转换酶 (ECE) 抑制剂,可抑制大 ET-1 向 ET-1 的转化,减轻小鼠结肠血管生成、组织损伤和炎症,且不改变小鼠的结肠缩短程度或髓过氧化物酶水平,可用于炎症性肠病 (结肠炎)、缺血性急性肾衰竭、急性心肌梗死及心肌缺血/再灌注损伤的研究。
产品编号: MS-O39301 CAS No.: 194542-49-9 分子式: C18H14ClN5O3S 分子量: 415.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SM19712 free acid 是一种具有口服活性的选择性内皮素转换酶 (ECE) 抑制剂,可抑制大 ET-1 向 ET-1 的转化,减轻小鼠结肠血管生成、组织损伤和炎症,且不改变小鼠的结肠缩短程度或髓过氧化物酶水平,可用于炎症性肠病 (结肠炎)、缺血性急性肾衰竭、急性心肌梗死及心肌缺血/再灌注损伤的研究。

生物实验数据

生物活性 SM19712 free acid is an orally active selective endothelin-converting enzyme (ECE) inhibitor that inhibits the conversion of big ET-1 to ET-1, attenuates colonic angiogenesis, tissue damage, and inflammation in mice without altering the degree of colonic shortening or myeloperoxidase levels in mice, and can be used for research on inflammatory bowel disease (colitis), ischemic acute renal failure, acute myocardial infarction, and myocardial ischemia/reperfusion injury.
体外研究
(In Vitro)

SM19712 free acid 可强效抑制从大鼠肺微粒体中溶解的 ECE,其 IC50 值为 42 nM。
SM19712 (10-300 μM) free acid 对 ECE 具有高特异性,在浓度高达 300 μM 时,对 NEP、ACE、13 种受试受体或 9 种受试酶均无显著抑制活性。
SM19712 (1-100 μM; 6 h) free acid 可浓度依赖性地抑制培养的猪主动脉内皮细胞中内源性 ET-1 的产生,其 IC50 为 31 μM。
SM19712 (100 μM) free acid 对内皮素转换酶具有高选择性,对中性内肽酶、血管紧张素转换酶、IV 型胶原酶及其他类别蛋白酶的抑制作用极弱。

体内研究
(In Vivo)

SM19712 (15 mg/kg/天;口服;每日给药;5-6 天) free acid 可部分减轻小鼠体内葡聚糖硫酸钠 (MS-A45736) 诱导的结肠炎。
SM19712 (3-30 mg/kg;静脉注射;闭塞前 5 分钟单次推注) free acid 可剂量依赖性地减轻 Sprague-Dawley 大鼠由缺血/再灌注诱导的急性肾衰竭。
SM19712 (0.3-30 mg/kg;静脉注射;单次给药) free acid 可呈剂量依赖性抑制大鼠体内 Big ET-1 诱导的升压反应。
SM19712 (10-30 mg/kg;口服;单次给药) free acid 可显著抑制大鼠中由 big ET-1 诱导的升压反应。
SM19712 (单次推注后持续输注,静脉给药,实验全程:推注剂量 25.9 mg/kg,输注速率 1.7 mg/kg/min) free acid 可显著降低冠状动脉闭塞再灌注诱导的家兔急性心肌梗死模型的梗死面积、血清 ET-1 升高水平及血清 CPK 活性。

Animal Model: C57BL/6 mice (~28 g; inflammatory bowel disease induced by 5% 40 kD Dextran Sodium Sulfate (DDS) in drinking water for 5-6 days)
Dosage: 15 mg/kg/day
Administration: p.o.; daily; 5-6 days
Result: Attenuated DSS-induced increases in colonic ET-1 immunostaining.
Reduced DSS-induced PECAM-1 immunostaining.
Attenuated DSS-induced histologic injury and inflammation.
Decreased the incidence of loose stools and fecal blood.
Reduced DSS-induced weight loss.
Significantly decreased the overall disease activity index in DSS-treated mice.
Did not significantly affect DSS-induced colon shortening or tissue myeloperoxidase activity.
Animal Model: Sprague-Dawley rats (male, 10 weeks old, 280-300 g, acute renal failure induced by right nephrectomy 2 weeks prior followed by 45-minute left renal artery and vein occlusion then reperfusion)
Dosage: 3; 10; 30 mg/kg
Administration: i.v.; single bolus 5 minutes before occlusion
Result: Reduced BUN, increased creatinine clearance, reduced urine flow, increased urinary osmolality, and reduced fractional excretion of sodium.
Attenuated tubular necrosis grade, proteinaceous casts grade, and medullary congestion grade.
Reduced renal ET-1 content.
Animal Model: Sprague-Dawley rats (male, 300-400 g, anesthetized, ganglionic-blocked, challenged with Big Edothelin-1)
Dosage: 0.3; 1; 3; 10; 30 mg/kg
Administration: i.v.; single dose
Result: Dose-dependently suppressed the pressor response induced by Big ET-1.
Significantly reduced the pressor response.
Had no effect on baseline pressure or the pressor response induced by mature ET-1.
Animal Model: Sprague-Dawley rats (male, 280-400 g, conscious then anesthetized, challenged with big endothelin-1)
Dosage: 10; 30 mg/kg
Administration: p.o.; single dose
Result: Produced a 37.2% suppression of the big ET-1-induced pressor response at 30 mg/kg.
Animal Model: New Zealand White rabbits (male, 2.6-3.5 kg, subjected to 30 minutes of coronary artery occlusion followed by 5 hours of reperfusion)
Dosage: 25.9 mg/kg (bolus); 1.7 mg/kg/min (continuous infusion)
Administration: i.v.; single bolus followed by continuous infusion; duration of experiment
Result: Significantly reduced myocardial infarct size, expressed as a percentage of both the left ventricle area and the area at risk, compared to vehicle.
Significantly attenuated the increase in serum ET-1 concentration and serum CPK activity seen in vehicle-treated rabbits during reperfusion.

化学信息

分子量 415.85
分子式 C18H14ClN5O3S
CAS No. 194542-49-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础